India, June 19 -- Addex Therapeutics Ltd. (ADXN) reported Thursday narrower net loss in its first quarter on the absence of prior year's loss from discontinued operations and lower expenses, despite sharply lower income from last year.
The Swiss clinical-stage biopharmaceutical company focused on neurological disorders reported that first-quarter net loss was 1.47 million Swiss francs, compared to loss of 3.09 million francs a year ago. Loss per share amounted to 0.01 franc, compared to loss of 0.03 franc a year ago.
The narrower loss primarily reflected the absence of prior year's discontinued loss of 2.35 million francs related to activities divested on April 2.
On a continuing operations basis, the prior year's loss was 0.74 million f...